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SI.]MMARY AND LOOK TOWARD THE FUTURE
This thésis deals with the effects of indomethacin on renal function and PRA in normal man
and in some pathological conditions. In order to measure some parameters of renal function
reliably, a simple and accurate method to determine GFR and ERPF had to be worked out. The
use of radiopharmaceuticals, thought to be excreted by glomerular filtration (e.g. r2sI-iothala-
mate) or by glomerular filtration and tubular secretion (e.g. 13tl-hippuran), simplifies the
measurement of GFR and ERPF respectively. A routine estimation of GFR and ERPF becomes
attractive if also the need for accurate urine collection by catheterization of the bladder can be
eliminated. In chapter I such a method is described. In this method GFR and ERPF are deter-
mined simultaneously with radiopharmaceuticals whereby the necessity of bladder catheteri-
zation is obviated. An additional advantage of the use of radio-iodinated hippuran is the
impossibility to exceed the maximal tubular secretory rate of hippuran by the doses normally
used. No precautions in this respect are necessary in patients with very low GFR. Special testing
must be carried out to assure that the free iodine content is minimal and patients should have
thyroid-blocking doses of lugol's solution the day before the study (with the exception of
patients with a known sensitivity to iodides). The radiation that patients receive from the
described procedure is minimal because the radioactivity is rapidly excreted. The estimated
radiation dose (rads) in patients with normal GFR amounts to [1-4]:












































Using radiopharmaceuticals, in chapter 2-4 it ís shown that indomethacin decreases GFR (and
FF) in normal individuals and in patients with renal disease, especially when they are sodium
depleted. Moreover, administration of indomethacin is shown to cause sodium and water
retention and a fall in PRA. These results are attributed to inhibition of the renal prostaglandin
synthesis. It may be asked whether this explanation fits in with the physiological role of the renal
prostaglandin synthesis.
It is generally accepted that blood pressure is maintained to a large extent through peripheral
vasoconstriction, regulated by the sympathetic vasoconstrictor tone, the secretion of catechol-
amines and the renin-angiotensin system. In low output and low pressure states, the renal vascular
bed is relatively free of vasoconstriction in order to preserve urine production and for instance the
homeostasis of potassium or pH. The renal ability to withstand vasoconstriction seems to be
caused by the renal prostaglandin synthesis. This synthesis, mainly located in the renal medulla, is
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promoted by renal ischemia, itself largely a result of an increased renin release in the renal cortex.
Thus, endogenous angiotensin II increases renal prostaglandin synthesis just like exogenous
angiotensin II. On the other hand, prostaglandins increase renin release, directly or secondary to
their vasodilator effect [5]. An equilibrium between these two vasoactive systems might be
achieved by prostaglandin lS-hydroxy dehydrogenase. This enzyme, present in the renal cortex,
possibly inactivates the prostaglandins that are synthes2ed in the renal medulla. In this way the
related renin-angiotensin and prostaglandin productions together can determine ultimately the
blood flow in outer and inner renal cortex and in the renal medulla, thereby influencing the
sodium and water balance.
From this point of view it is explainable that inhibition of the renal prostaglandin synthesis by
indomethacin is accompanied by a decrease in GFR, a retention of sodium and water and a fall in
PRA. It is also understandable that these effects are more pronounced when the renin-angiotensin
system has been stimulated. In vivo, inactivation of prostaglandin 15-hydroxydehydrogenase by
furosemide (already demonstrated in vitro), will result in an immediate increase in PRA, as in this
condition the vasodilatory prostaglandins influence the cortical nephrons unopposed. As shown in
chapter 6, this effect of furosemide on PRA can be abolished by a preceding prostaglandin
synthesis inhibition. Normally this will not be accompanied by a clearly diminished excretion of
sodium and water as furosemide inhibits sodium transport along the whole nephron. Only in
Bartter's syndrome and in patients with severe nephrotic syndrome, conditions both characterized
by hyperreninemia and hyperaldosteronism, a preceding prostaglandin synthesis inhibition by
indomethacin results in a diminished natriuretic and diuretic activity of furosemide. Probably in
these patients cortical hyperemia by furosemide, an effect enhanced by the already elevated
prostaglandin synthesis and resulting in diminished proximal tubular sodium reabsorption,
attributes to the saluretic activity of the drug.
In chapter 3 and 4 it is also shown that indomethacin administration to patients with a
nephrotic syndrome of various origin induces a marked and abrupt decrease in urinary protein
loss, associated with an increase in selectivity of the residual proteinuria. One may postulate that
these effects are the result of a change in the glomerular ultrafiltration coefficient (K), a change
in glomerular plasma flow, a change in the effective transcapillary hydraulic pressure difference
(À P), or a change in the fixed negative charges on the glomerular capillary wall. The latter seems
to be unlikely as the effect of indomethacin on proteinuria is enhanced by sodium depletion,
while sodium depletion itself does not influence urinary protein loss. As indomethacin inhibits
prostaglandin synthesis and decreases PRA immediately, a decrease in the effective transcapillary
hydraulic pressure difference, possibly restricted to the juxtamedullary nephrons, would explain
the decrease in proteinuria by this anti-inflammatory drug in the same way as a renin - or
angiotensin-induced increase in the intraglomerular pressure induces an increase in (macro-
molecular) proteinuria (accompanied by an increase in FF) [0]. fne decrease in FF, pointing to
(an increase of) filtration pressure disequilibrium, is in support of this hypothesis. Measurement
of glomerular plasma flow, average effective transcapillary hydraulic pressure difference and
average ffective oncotic pressure difference (A r), before and after indomethacin administration
to nephrotic animals, seems to be of prime importance in the evaluation of the mechanism that
trnderlies the indomethacin-induced ecrease in transglomerular passage of plasma proteins.
A possible favorable long-term effect of indomethacin on the course of some types of renal
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diseases, e.g. by inhibition of the chemotactic migration of leucocytes or of the maturation of
T-lymphocytes and/or by stabilization of lysosomal membranes [7] warrants controlled trials. A
modification of the natural history of the renal disease by an inhibition of the platelet aggregation
seems to be unlikely as mounting evidence suggests that urinary fibrin-fibrinogen-related antigen
excretion in glomerulonephritis is derived predominantly from increased filtration of plasma
fibrinogen rather than from breakdown of intraglomerular fibrin [8]. Therefore, the excretion of
fibrin-fibrinogen degradation products in nephrotic patients before and during indomethacin
administration has to be related to the selectivity of the proteinuria.
Administration of other prostaglandin synthesis inhibitors such as meclofenamate, diclofenac
sodium and ibuprofen to (sodium depleted) patients with nephrotic syndrome, will be helpful to
substantiate the assumption that the initial effect of indomethacin on proteinuria depends
exclusively on the inhibition of the prostaglandin synthesis. In support ofthis hypothesis are the
renal effects of other potent inhibitors such as aminophenazone (pyramidon$, phenylbutazone,
salicylates [9] and fenoprofen [10].
It also would be of importance to measure the total amount of prostaglandins produced in
sodium depleted nephrotic patients and to compare this with the prostaglandin production during
indomethacin administration. In vitro a 100 per cent inhibition of prostaglandin synthesis was
found at an indomethacin concentration of l.0pg/rni Itt]. fne determination of prostaglandin
metabolites in 24-hours' urine [12] or the determination of PGE, in (renal) blood samples by
combined gas-liquid chromatography - mass spectrometry [13] and the determination of
indomethacin serum concentrations [14], may be of value to tind the optimal prostaglandin
synthesis inhibiting dose of indomethacin, especially when GFR is normal.
Peptic ulceration, a serious side effect of prolonged administration of indomethacin, probably
can be prevented by l5(R)15 methylprostaglandin E, orally. It is not known whether oral
administration of this analogue influences GFR or urinary protein loss. The availability of
synthetic prostaglandins [15], including PGE, makes also possible the study on the effects of
oral or intravenous administration of these compounds to (indomethacin treated) animals and
patients with nephrotic syndrome.
Finally, the cause of hyperprostaglandinism in Bartter's syndrome (chapter 5) needs
elucidation. As argued in chapter 6, an absence of the prostaglandin inactivating enzyme, at least
in one patient with that condition, seems to be unlikely. It is quite possible that the state of
hyperprostaglandinism, as expressed among other things by an elevation of urinary PGE2 [16,
l7], is secondary to other physiological abnormalities, i.e. Bartter's syndrome may be a
heterogenous disorder. However, measurement of PGE2 (and PGF2.) in peripheral and renal vein
blood remains of prime importance in order to establish whether one has to do with a renal or
general state of hyperprostaglandinism.
l .
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